HHS Watchdog Office Steps Up Focus on Drug Pricing

November 10, 2016

Ed Silverman reported in STAT that “to address rising concerns about prescription medicines, the watchdog arm of the US Department of Health Human Services is adding to its list of pharmaceutical issues to be examined.” One of the issues the HHS Office of Inspector General (OIG) looking at is how much money could be saved if drug makers paid rebates for medicines dispensed through the Medicare Part D program at hospitals that participate in the 340B Drug Pricing Program. The HHS OIG does not propose programs, but its ability to research trends holds the potential for spurring change that can affect how the federal government develops policies, manages budgets, and corrects problems.